Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Videos Previous | All Articles This Week | Next
This article originally posted 14 July, 2012 and appeared in  DietCardiovascular HealthMedicationBlood Glucose ControlGLP-1 Receptor Agonist TherapyPublic Health and PolicyMedication VideosThe "Best A1c" VideosStanley Schwartz, MDInsulinGlucose Monitoring

Stanley Schwartz, MD, Q4: What Is the Best A1c?

Dr. Schwartz discusses what the best A1c might be for a patient with diabetes, the current ADA guidelines, and how the guidelines have changed over the years taking into account different clinical data and criteria, including measurements of retinopathy and CV health. He also discusses the possibility of getting A1c's even lower in the future, especially with better screening, prevention with lifestyle changes, and treating prediabetes.

More videos with Dr. Schwartz:

Stanley Schwartz, MD, Introduction

Preventing Hypoglycemia in the Hospital Using Incretins

Tips for Maximizing Medication Effectiveness and Patient Health

How Exercise Fits In with Diabetes Control

Advertisement
Stanley Schwartz, MD, has been awarded the honor of being a TOP DOC by Philadelphia Magazine many times over the years, including 2009, 2010 and 2011 for the treatment of diabetes and metabolic syndrome. For over 30 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute. Dr. Stanley Schwartz is a new Affiliate of the Main Line Health System, and an Emeritus Associate Professor of Medicine at the University of Pennsylvania, currently in a private practice in Ardmore, Pa. Dr. Schwartz received his MD in 1973 from the University of Chicago in Chicago, Illinois. He then completed his residency at the University of Pennsylvania, followed by a fellowship in endocrinology and metabolism at the University of Chicago.
 
Dr. Schwartz serves on the following Advisory Boards: Eli Lilly, Inc.; Amylin Pharmaceuticals; Takeda; Janssen; sanofi-aventis; and Santarus
 
He is also part of the following speaker's bureaus: Merck; Eli Lilly;  Amylin Pharmaceuticals; Takeda; Santarus; BMS; Astra-Zeneca; and Novo Novartis.
 
Diabetes In Control is honored to also have Dr. Schwartz on our Advisory Board as well as a contributor to our newsletters.

   

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 14 July, 2012 and appeared in  DietCardiovascular HealthMedicationBlood Glucose ControlGLP-1 Receptor Agonist TherapyPublic Health and PolicyMedication VideosThe "Best A1c" VideosStanley Schwartz, MDInsulinGlucose Monitoring

Past five issues: Diabetes Clinical Mastery Series Issue 141 | Issue 681 | Diabetes Clinical Mastery Series Issue 140 | Issue 680 | Diabetes Clinical Mastery Series Issue 139 |

 
Diabetes In Control Advertisers
 
Cast Your Vote
If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

Navigate Diabetes In Control
CME/CE of the Week
Jeffrey M. Robbins, DPM

Category: General Diabetes
Credits: .5



Search Articles On Diabetes In Control